Beacon Pointe Advisors, LLC
Position in HALO — Halozyme Therapeutics, Inc.
CIK 1744317
NEWPORT BEACH, CA
Position in HALO
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$679,067
New position
Shares Held
10,507
first reported quarter
Ownership
0.009%
of shares outstanding
% of Portfolio
0.01%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2026
1 quarter on record
Voting authority
Sole 0.ToString("F0")%
Shared 0.ToString("F0")%
None 100.ToString("F0")%
Position in Biotechnology
Healthcare · as of Mar 31, 2026Beacon Pointe Advisors, LLC holds $39,649,374 across 25 Biotechnology names. HALO ranks #7 (1.7% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | REGN |
Regeneron Pharmaceuticals, Inc.
|
19,460 | $15,035,574 | |
| 2 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
17,894 | $7,990,386 | |
| 3 | INCY |
Incyte Corp
|
73,301 | $6,899,090 | |
| 4 | NUVB |
Nuvation Bio Inc.
|
643,734 | $2,761,618 | |
| 5 | SMMT |
Summit Therapeutics Inc.
|
94,394 | $1,789,710 | |
| 6 | BNTX |
BioNTech SE
|
16,673 | $1,481,896 | |
| 7 | HALO |
Halozyme Therapeutics, Inc.
This page
|
10,507 | $679,067 | |
| 8 | CRSP |
CRISPR Therapeutics AG
|
12,085 | $574,883 |
All Filings in HALO
Export CSV
1 filing row on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $679,067 | 10,507 | Shares | Sole | 2026-05-15 | |
| No filing history on record for this holder in this stock. | ||||||